Vorasidenib: all 23 studies that test it
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)Not yet recruitingNCT07877415Phase 1
- VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsNot yet recruitingNCT07629089Phase 1
- Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationRecruitingNCT07286292Phase 2
- Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control ParticipantsRecruitingNCT07250633Phase 1
- Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerRecruitingNCT07215910Phase 3
- Vorasidenib Maintenance for IDH Mutant AstrocytomaRecruitingNCT06809322Phase 3
- ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade GliomasRecruitingNCT05609994Phase 1
- Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)Active, not recruitingNCT04164901Phase 3Results posted
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female ParticipantsCompletedNCT07235774Phase 1
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsCompletedNCT07235748Phase 1
- A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)Active, not recruitingNCT06969352Not applicable
- Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationActive, not recruitingNCT06780930Phase 3
- Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant GliomaActive, not recruitingNCT06478212Phase 1/2
- A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsCompletedNCT05843708Phase 1
- A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionCompletedNCT05674474Phase 1
- Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruitingNCT05484622Phase 1
- A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian ParticipantsCompletedNCT04145128Phase 1
- A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881CompletedNCT04128787Phase 1
- A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy AdultsCompletedNCT04015687Phase 1
- A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881CompletedNCT03960502Phase 1
- Study of AG-120 and AG-881 in Subjects With Low Grade GliomaCompletedNCT03343197Phase 1
- Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationCompletedNCT02492737Phase 1
- Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 MutationCompletedNCT02481154Phase 1